Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib hydrochloride + sintilimab + gemcitabine + cisplatin
- Development stage
- Phase 2
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy, often referred to as the SAGC regimen, is a multi-modality treatment being evaluated for advanced biliary tract cancer. It consists of **anlotinib hydrochloride**, an oral small-molecule multi-target tyrosine kinase inhibitor that inhibits VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit; **sintilimab**, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses; and the standard chemotherapy doublet of **gemcitabine** and **cisplatin**. The regimen aims to provide synergistic effects by combining anti-angiogenesis, immune checkpoint inhibition, and cytotoxic chemotherapy. A Phase II trial (NCT04300959) led by Zhejiang Cancer Hospital demonstrated that this four-drug combination significantly improved progression-free survival and objective response rates compared to gemcitabine and cisplatin alone as a first-line treatment for unresectable or metastatic biliary tract cancer.
- Other names
- Anlotinib + Sintilimab + GemCisAnlotinib + PD-1 + Gemcitabine + CisplatinAnlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus Cisplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on anlotinib hydrochloride + sintilimab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib hydrochloride + sintilimab + gemcitabine + cisplatin.